MiMedx Group, Inc (NASDAQ:MDXG) Receives $8.50 Average PT from Brokerages

Shares of MiMedx Group, Inc (NASDAQ:MDXG) have received a consensus recommendation of “Moderate Buy” from the seven analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $8.50.

MDXG has been the subject of several recent research reports. Craig Hallum lowered their price objective on MiMedx Group from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Citizens Jmp lowered their price objective on MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a research report on Thursday, April 30th. Weiss Ratings downgraded MiMedx Group from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 4th. Wall Street Zen downgraded MiMedx Group from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Finally, Cantor Fitzgerald lowered their price objective on MiMedx Group from $12.00 to $8.00 and set an “overweight” rating for the company in a research report on Tuesday, February 17th.

Institutional Trading of MiMedx Group

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Legato Capital Management LLC lifted its holdings in MiMedx Group by 18.5% in the 3rd quarter. Legato Capital Management LLC now owns 17,341 shares of the company’s stock worth $121,000 after buying an additional 2,708 shares during the period. SkyView Investment Advisors LLC lifted its holdings in MiMedx Group by 3.6% in the 2nd quarter. SkyView Investment Advisors LLC now owns 87,734 shares of the company’s stock worth $523,000 after buying an additional 3,032 shares during the period. Rafferty Asset Management LLC lifted its holdings in MiMedx Group by 4.6% in the 4th quarter. Rafferty Asset Management LLC now owns 69,304 shares of the company’s stock worth $469,000 after buying an additional 3,064 shares during the period. Aviva PLC lifted its holdings in MiMedx Group by 4.7% in the 4th quarter. Aviva PLC now owns 71,234 shares of the company’s stock worth $482,000 after buying an additional 3,211 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in MiMedx Group by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock worth $559,000 after buying an additional 4,049 shares during the period. Institutional investors own 79.15% of the company’s stock.

MiMedx Group Price Performance

MDXG opened at $3.56 on Friday. The stock’s 50 day simple moving average is $3.86 and its 200 day simple moving average is $5.43. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.39 and a quick ratio of 4.81. MiMedx Group has a 1 year low of $3.03 and a 1 year high of $7.99. The firm has a market cap of $530.26 million, a price-to-earnings ratio of 17.80 and a beta of 1.46.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings data on Wednesday, April 29th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.02. MiMedx Group had a return on equity of 21.03% and a net margin of 7.88%.The firm had revenue of $58.99 million during the quarter, compared to the consensus estimate of $65.80 million. As a group, analysts predict that MiMedx Group will post -0.01 earnings per share for the current year.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.